Drugs / HM30181A-UK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04013217 | Jul 2019 → Mar 2022 | cancer | Health Hope Pharma | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM30181A-UK | “Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK” NCT04013217 ↗ |